Detalhe da pesquisa
1.
Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS).
J Eur Acad Dermatol Venereol
; 37(5): 1017-1027, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-36695061
2.
Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study.
Dermatol Ther
; 35(6): e15488, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35384168
3.
Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry.
Allergy
; 76(6): 1813-1824, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34152613
4.
Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study.
Acta Derm Venereol
; 101(10): adv00576, 2021 Oct 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-33903916
5.
Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literature.
Dermatol Ther
; 32(3): e12899, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30969010
6.
Successful treatment of psoriatic crumbly nails with ustekinumab.
Dermatol Ther
; 32(3): e12914, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30968520
7.
Successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: A case series.
J Eur Acad Dermatol Venereol
; 2024 Feb 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38421043
8.
Myasthenia gravis associated with muscle-specific kinase antibodies in a patient treated with interleukin-17 inhibitor.
Neurol Sci
; 44(3): 1105-1107, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36357816
9.
Alexithymia and Plaque Psoriasis: Preliminary Investigation in a Clinical Sample of 250 Patients.
Dermatology
; 232(6): 648-654, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-28152541
10.
IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis.
Dermatology
; 232(2): 230-6, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26678060
11.
What happened after the clinical trials: long-term safety and efficacy of ustekinumab in daily clinical practice.
Dermatology
; 229(4): 324-32, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25402662
12.
Successful long-term guselkumab treatment of severe plaque psoriasis in patients with class III obesity: A case series.
Skin Health Dis
; 4(1): e289, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38312241
13.
Dupilumab for Treatment of Prurigo Nodularis: Real-Life Effectiveness for up to 84 Weeks.
J Clin Med
; 13(3)2024 Feb 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38337572
14.
Efficacy and Safety of Dupilumab in the Treatment of Hand Eczema: A Retrospective Study.
J Clin Med
; 13(7)2024 Mar 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38610641
15.
A Multidisciplinary Approach Is Beneficial in Atopic Dermatitis.
Dermatol Ther (Heidelb)
; 2024 May 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38811470
16.
Long-Term Effectiveness of Brodalumab for the Treatment of Moderate-To-Severe Psoriasis: A Real-Life Multicenter Study of Up to 3 Years in a Real-Life Italian Cohort.
Dermatol Pract Concept
; 14(2)2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38810071
17.
Evaluating the Clinical Meaning of Dermatology Life Quality Index Scores Between Different Phenotypes of Atopic Dermatitis in Patients Before and After Biologic Therapy With Dupilumab.
Dermatitis
; 2024 Apr 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38669092
18.
Anti-Herpes zoster vaccination in patients with dermatologic diseases: a position statement from the Italian SIDeMaST group of sexually transmitted, infectious and tropical diseases.
Ital J Dermatol Venerol
; 2024 May 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38780911
19.
Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER - study).
J Dermatolog Treat
; 35(1): 2319304, 2024 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38413097
20.
Deucravacitinib, a selective tyrosine kinase 2 inhibitor, for the treatment of moderate-to-severe plaque psoriasis.
Expert Opin Pharmacother
; 24(9): 981-988, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37147879